AU2018276566A1 - Pharmaceutical composition comprising PDE9 inhibitor - Google Patents
Pharmaceutical composition comprising PDE9 inhibitor Download PDFInfo
- Publication number
- AU2018276566A1 AU2018276566A1 AU2018276566A AU2018276566A AU2018276566A1 AU 2018276566 A1 AU2018276566 A1 AU 2018276566A1 AU 2018276566 A AU2018276566 A AU 2018276566A AU 2018276566 A AU2018276566 A AU 2018276566A AU 2018276566 A1 AU2018276566 A1 AU 2018276566A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- subjects
- auc
- mean
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- NWHVINKBYGQMAT-QRGRWYIGSA-N Cc1cnc(C)c(C)c1-c1cc(NC(C2C=NN([C@@H]3COCC3)C22)=C)c2cc1 Chemical compound Cc1cnc(C)c(C)c1-c1cc(NC(C2C=NN([C@@H]3COCC3)C22)=C)c2cc1 NWHVINKBYGQMAT-QRGRWYIGSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762513690P | 2017-06-01 | 2017-06-01 | |
| US62/513,690 | 2017-06-01 | ||
| PCT/JP2018/020643 WO2018221546A1 (en) | 2017-06-01 | 2018-05-30 | Pharmaceutical composition comprising pde9 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2018276566A1 true AU2018276566A1 (en) | 2019-11-07 |
Family
ID=64455959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018276566A Abandoned AU2018276566A1 (en) | 2017-06-01 | 2018-05-30 | Pharmaceutical composition comprising PDE9 inhibitor |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11484502B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3630113A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7293129B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200010211A (cg-RX-API-DMAC7.html) |
| CN (2) | CN116585316A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018276566A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019023557A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3059539A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019013198A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2019135261A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201909359YA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018221546A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200010220A (ko) | 2017-06-01 | 2020-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제 |
| BR112019023569A2 (pt) | 2017-06-01 | 2020-06-02 | Eisai R&D Management Co., Ltd. | Agente terapêutico da demência combinando derivados de pirazoloquinolina e donepezila |
| JP7177772B2 (ja) | 2017-06-01 | 2022-11-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤 |
| KR20240101561A (ko) | 2021-10-14 | 2024-07-02 | 인사이트 코포레이션 | Kras의 저해제로서의 퀴놀린 화합물 |
| WO2024107445A1 (en) * | 2022-11-15 | 2024-05-23 | Freedom Biosciences, Inc. | Enhancement of the efficacy of serotonergic psychedelic drugs in the treatment or prevention of certain neuropsychiatric disorders through inhibition of type-9 phosphodiesterases |
| CN119302958B (zh) * | 2023-12-01 | 2025-10-21 | 郑州大学第一附属医院 | 含有bay 73-6691或其衍生物的药物制剂在制备治疗脑损伤疾病药物中的应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5318759A (en) | 1976-08-02 | 1978-02-21 | Nisshin Oil Mills Ltd | Method of making fried beancurd |
| JPH05132484A (ja) | 1991-04-26 | 1993-05-28 | Otsuka Pharmaceut Factory Inc | ピラゾロキノリン及びピラゾロナフチリジン誘導体 |
| DE69518075T2 (de) | 1994-05-24 | 2001-03-22 | F. Hoffmann-La Roche Ag, Basel | Tricyclische dicarbonylderivate |
| DE19642591A1 (de) | 1996-10-15 | 1998-04-16 | Basf Ag | Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung |
| HN2002000317A (es) | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
| EP1537106A1 (en) | 2002-08-07 | 2005-06-08 | Mitsubishi Pharma Corporation | Dihydropyrazolopyridine compounds |
| DE10238722A1 (de) * | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| DE102004004142A1 (de) | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine |
| RU2426734C2 (ru) | 2003-10-03 | 2011-08-20 | Зм Инновейтив Пропертиз Компани | Пиразолопиридины и их аналоги |
| US20060035920A1 (en) | 2004-05-28 | 2006-02-16 | Millennium Pharmaceuticals, Inc. | Chk-1 inhibitors |
| JP2006045118A (ja) | 2004-08-04 | 2006-02-16 | Mochida Pharmaceut Co Ltd | 新規ピラゾロキノロン誘導体 |
| WO2007032466A1 (ja) | 2005-09-15 | 2007-03-22 | Aska Pharmaceutical Co., Ltd. | 複素環化合物、その製造方法並びに用途 |
| TW200808741A (en) | 2006-06-09 | 2008-02-16 | Wyeth Corp | 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts |
| WO2007146073A2 (en) | 2006-06-09 | 2007-12-21 | Wyeth | Method for enhancing cognitive function |
| WO2008072779A1 (ja) | 2006-12-13 | 2008-06-19 | Aska Pharmaceutical Co., Ltd. | キノキサリン誘導体 |
| AU2007332439A1 (en) | 2006-12-13 | 2008-06-19 | Aska Pharmaceutical Co., Ltd. | Therapeutic agent for urinary tract disease |
| PT2152712E (pt) | 2007-05-11 | 2012-02-29 | Pfizer | Compostos amino-heterocíclicos |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| CN102143965A (zh) | 2008-09-08 | 2011-08-03 | 贝林格尔.英格海姆国际有限公司 | 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途 |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基-雜環化合物 |
| AU2010219598A1 (en) | 2009-03-05 | 2011-09-22 | Astellas Pharma Inc. | Quinoxaline compounds |
| UY32531A (es) | 2009-03-31 | 2010-10-29 | Boehringer Ingelheim Int | Nuevos compuestos para el tratamiento de trastornos del snc |
| LT2419104T (lt) | 2009-04-13 | 2018-02-12 | Theravance Biopharma R&D Ip, Llc | 5-ht4 receptoriaus agonistų ir acetilcholinesterazės inhibitorių deriniai, skirti pažinimo sutrikimų gydymui |
| US8880976B2 (en) | 2009-09-25 | 2014-11-04 | Stmicroelectronics, Inc. | Method and apparatus for encoding LBA information into the parity of a LDPC system |
| BR112013003097B1 (pt) | 2010-08-12 | 2021-03-16 | Boehringer Ingelheim International Gmbh | 6-cicloalquil-pirazolopirimidinonas e composição farmacêutica |
| ES2583528T3 (es) | 2010-09-07 | 2016-09-21 | Astellas Pharma Inc. | Compuesto de pirazoloquinolina |
| US20130040971A1 (en) | 2011-02-14 | 2013-02-14 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders |
| JP6042060B2 (ja) | 2011-09-26 | 2016-12-14 | サノフイ | ピラゾロキノリノン誘導体、その調製および治療上の使用 |
| SI2573073T1 (sl) | 2011-09-26 | 2015-02-27 | Sanofi | Pirazolokinolinonski derivati, njihova priprava in njihova terapevtska uporaba |
| JP5938299B2 (ja) | 2011-10-05 | 2016-06-22 | ダイセルポリマー株式会社 | 繊維強化樹脂組成物 |
| CN103930423B (zh) * | 2011-10-07 | 2015-09-16 | 卫材Rd管理有限公司 | 吡唑并喹啉衍生物 |
| JP5666755B1 (ja) | 2013-04-05 | 2015-02-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロキノリン誘導体の塩およびその結晶 |
| WO2016179569A1 (en) | 2015-05-07 | 2016-11-10 | Axovant Sciences Ltd. | Compositions and methods of treating a neurodegenerative disease |
| KR20200010220A (ko) | 2017-06-01 | 2020-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제 |
| JP7177772B2 (ja) | 2017-06-01 | 2022-11-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤 |
| BR112019023569A2 (pt) | 2017-06-01 | 2020-06-02 | Eisai R&D Management Co., Ltd. | Agente terapêutico da demência combinando derivados de pirazoloquinolina e donepezila |
-
2018
- 2018-05-30 CN CN202310559688.6A patent/CN116585316A/zh active Pending
- 2018-05-30 MX MX2019013198A patent/MX2019013198A/es unknown
- 2018-05-30 RU RU2019135261A patent/RU2019135261A/ru unknown
- 2018-05-30 WO PCT/JP2018/020643 patent/WO2018221546A1/en not_active Ceased
- 2018-05-30 SG SG11201909359Y patent/SG11201909359YA/en unknown
- 2018-05-30 AU AU2018276566A patent/AU2018276566A1/en not_active Abandoned
- 2018-05-30 CN CN201880027744.9A patent/CN110545812A/zh active Pending
- 2018-05-30 KR KR1020197032163A patent/KR20200010211A/ko not_active Ceased
- 2018-05-30 BR BR112019023557-4A patent/BR112019023557A2/pt not_active IP Right Cessation
- 2018-05-30 JP JP2019559117A patent/JP7293129B2/ja active Active
- 2018-05-30 EP EP18809656.4A patent/EP3630113A4/en active Pending
- 2018-05-30 CA CA3059539A patent/CA3059539A1/en active Pending
- 2018-05-30 US US16/609,514 patent/US11484502B2/en active Active
-
2022
- 2022-06-03 US US17/831,863 patent/US20220378706A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020521726A (ja) | 2020-07-27 |
| KR20200010211A (ko) | 2020-01-30 |
| CN116585316A (zh) | 2023-08-15 |
| JP7293129B2 (ja) | 2023-06-19 |
| CN110545812A (zh) | 2019-12-06 |
| CA3059539A1 (en) | 2018-12-06 |
| EP3630113A4 (en) | 2021-02-24 |
| SG11201909359YA (en) | 2019-11-28 |
| US20220378706A1 (en) | 2022-12-01 |
| RU2019135261A3 (cg-RX-API-DMAC7.html) | 2021-09-08 |
| BR112019023557A2 (pt) | 2020-06-02 |
| EP3630113A1 (en) | 2020-04-08 |
| US20200078306A1 (en) | 2020-03-12 |
| US11484502B2 (en) | 2022-11-01 |
| WO2018221546A1 (en) | 2018-12-06 |
| MX2019013198A (es) | 2020-01-20 |
| RU2019135261A (ru) | 2021-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11484502B2 (en) | Pharmaceutical composition comprising PDE9 inhibitor | |
| Dunbar et al. | A comparison of paroxetine, imipramine and placebo in depressed out-patients | |
| EP1741446B1 (en) | Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents | |
| EP2278972B1 (en) | Treatment for neurological and mental disorders | |
| Gerra et al. | Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo‐controlled study | |
| EP4054620B1 (en) | Semaglutide in the treatment of alzheimer's dementia | |
| JP7765970B2 (ja) | ブルトン型チロシンキナーゼ阻害剤を使用したシェーグレン症候群を処置する方法 | |
| JP2023181398A (ja) | 認知症および神経変性状態における興奮、精神病および認知機能低下のためのシクロベンザプリン処置 | |
| CN113557022A (zh) | 用罗达司他乙酯治疗肺动脉高压的给药方案和方法 | |
| WO2008047340A1 (en) | Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders | |
| CN117715641A (zh) | 用神经活性类固醇进行治疗的方法 | |
| TWI831896B (zh) | 用於治療多巴胺性cns病症之ly3154207劑量療法 | |
| TWI289060B (en) | Pharmaceutical composition for improving the recovery of post-stroke patients | |
| DE602004005000T2 (de) | Methode zur behandlung von niereninsuffizienz | |
| Valsecchi et al. | Paliperidone extended-release in the short-and long-term treatment of schizophrenia | |
| KR20230041006A (ko) | 오피오이드 사용 감소 치료에 사용하기 위한 mglur5 길항제 마보글루란트 | |
| US20230123140A1 (en) | Dose treatments of tauopathies | |
| HK40075453A (en) | Semaglutide in the treatment of alzheimer's dementia | |
| CN121511089A (zh) | 伊博格碱治疗 | |
| Kelemen et al. | Central nervous system stimulants and anorectic agents | |
| HK40062167A (en) | A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl | |
| HK1102405B (en) | Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents | |
| HK1116070A (en) | Use of paliperidone for the treatment of psychiatric patients with reduced hepatic function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |